Roundhill Investments - GLP-1 & Weight Loss ETF
Limited financial coverage for OZEM.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
About the company
Roundhill considers weight loss medications, particularly GLP-1 agonists, to be among the most groundbreaking innovations currently reshaping the global pharmaceutical landscape. This conviction underpins the Roundhill GLP-1 & Weight Loss ETF (OZEM), which is distinguished as the world's inaugural ETF exclusively focused on the GLP-1 and broader weight management sector. Notably, OZEM employs an active management approach.
- IPO
- 2024
- HQ
- New York, NY, US
Price Chart
- Market Cap
- $43.11M
- Div Yield
- 1.22%
- 52W High
- $37.15
- 52W Low
- $23.22
- 50D MA
- $31.14
- 200D MA
- $31.81
- Beta
- 0.41
- Avg Volume
- 22.25K
Get TickerSpark's AI analysis on OZEM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our OZEM coverage
Recent articles, reports, and earnings notes.
No research on OZEM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OZEM report →Similar companies
Peers in the same neighborhood.